Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.

Authors: Guillermo de Velasco, Laurence Albiges, Thomas Powles, Cristina Suárez, Katriina Johanna Jalkanen, Mauricio Burotto, Pooja Ghatalia, Roberto Iacovelli, Elaine T Lam, Elena Verzoni, Mahmut Gumus, Walter Michael Stadler, Christian K. Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Jingyi Lin, Rodolfo F. Perini, Donna Vickery, Brian I. Rini, Toni K. Choueiri

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.538

Source: Full article


Abstract

538